FBIO
Fortress Biotech, Inc.
Price Chart
Latest Quote
$3.06
+0.07 (+2.51%)
Current Price
| Previous Close | $2.99 |
| Open | $2.99 |
| Day High | $3.12 |
| Day Low | $2.96 |
| Volume | 466,544 |
Stock Information
| Shares Outstanding | 33.22M |
| Total Debt | $53.63M |
| Cash Equivalents | $255.84M |
| Revenue | $66.16M |
| Net Income | $119.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $101.82M |
| P/E Ratio | 0.95 |
| EPS (TTM) | $3.23 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-62.72M |
| Sales | $66.16M |
| Income | $119.20M |
| Book/sh | $4.89 |
| Cash/sh | $7.70 |
| Employees | 78 |
Financial Ratios
| Quick Ratio | 2.72 |
| Current Ratio | 2.86 |
| Debt/Eq | 26.50 |
Returns & Margins
| ROA | -13.00% |
| ROE | 109.80% |
| Gross Margin | 53.36% |
| Operating Margin | -48.25% |
| Profit Margin | 193.12% |
Ownership
| Insider Ownership | 22.79% |
| Institutional Ownership | 24.77% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.74 |
| P/S | 1.54 |
| P/B | 0.63 |
Analyst Data
| Recommendation | none |
| Target Price | $11.00 |
Technical Indicators
| SMA20 | $2.80 |
| SMA50 | $2.54 |
| SMA200 | $3.01 |
| RSI | 68.82 |
| ATR | 0.1793 |
| Shares Float | 23.09M |
| Short Float | 19.85% |
| Short Ratio | 13.73 |
| Volatility | 1.24 |
| Rel Volume | 1.05 |
Performance History
| Week | +10.65% |
| Month | +15.66% |
| Quarter | +2.51% |
| 6 Months | -10.64% |
| YTD | -23.95% |
| Year | +69.34% |
| 3 Years | -67.04% |
| 5 Years | -94.64% |
| 10 Years | -92.14% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $3.07 | 466,544 |
| 2026-06-18 | $2.99 | 372,100 |
| 2026-06-17 | $3.07 | 689,300 |
| 2026-06-16 | $2.93 | 374,900 |
| 2026-06-15 | $2.86 | 463,800 |
| 2026-06-12 | $2.77 | 284,900 |
| 2026-06-11 | $2.76 | 392,900 |
| 2026-06-10 | $2.77 | 300,700 |
| 2026-06-09 | $2.93 | 405,000 |
| 2026-06-08 | $2.85 | 982,400 |
| 2026-06-05 | $2.65 | 326,900 |
| 2026-06-04 | $2.77 | 424,700 |
| 2026-06-03 | $2.61 | 282,200 |
| 2026-06-02 | $2.65 | 527,100 |
| 2026-06-01 | $2.57 | 809,200 |
| 2026-05-29 | $2.80 | 354,600 |
| 2026-05-28 | $2.81 | 379,400 |
| 2026-05-27 | $2.76 | 254,600 |
| 2026-05-26 | $2.69 | 464,500 |
| 2026-05-22 | $2.74 | 305,100 |
About Fortress Biotech, Inc.
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
đ° Latest News
Fortress Biotechâs Cyprium enters agreement to sell PRV for $205M
TipRanks âĸ 2026-02-24T13:53:18Z
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability
Simply Wall St. âĸ 2026-01-18T12:51:46Z
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Zacks âĸ 2025-11-14T14:40:02Z
Fortress Biotech: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-14T13:40:52ZKamada (KMDA) Misses Q3 Earnings Estimates
Zacks âĸ 2025-11-10T13:15:03Z
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-06T22:45:04Z
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-04T22:15:03Z
Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
Zacks âĸ 2025-10-30T12:15:02Z
Top Midday Decliners
MT Newswires âĸ 2025-10-01T18:10:24ZFortress Biotech Gets US FDA Letter for Deficiencies at Manufacturing Site; Stock Down 30% Premarket
MT Newswires âĸ 2025-10-01T13:02:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $20,521,000 | $19,839,000 | $20,663,000 | $30,775,000 |
| Cost Of Revenue | $20,924,000 | $20,879,000 | $22,893,000 | $30,775,000 |
| Total Revenue | $63,262,000 | $57,675,000 | $84,513,000 | $75,743,000 |
| Operating Revenue | $61,239,000 | $56,675,000 | $64,994,000 | $73,069,000 |
| Expenses | ||||
| Interest Expense | $8,709,000 | $11,588,000 | $11,915,000 | $10,417,000 |
| Total Expenses | $133,483,000 | $168,915,000 | $223,712,000 | $279,307,000 |
| Other Income Expense | $44,307,000 | $1,541,000 | $-2,122,000 | $2,344,000 |
| Other Non Operating Income Expenses | $17,578,000 | $1,318,000 | $-3,403,000 | $1,215,000 |
| Net Non Operating Interest Income Expense | $-7,621,000 | $-10,844,000 | $-12,312,000 | $-12,244,000 |
| Total Other Finance Cost | $1,397,000 | $1,939,000 | $3,400,000 | $3,225,000 |
| Interest Expense Non Operating | $8,709,000 | $11,588,000 | $11,915,000 | $10,417,000 |
| Operating Expense | $112,559,000 | $148,036,000 | $200,819,000 | $248,532,000 |
| Other Operating Expenses | - | - | - | $-1,304,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $6,815,000 | $-45,997,000 | $-60,637,000 | $-86,575,000 |
| Net Interest Income | $-7,621,000 | $-10,844,000 | $-12,312,000 | $-12,244,000 |
| Interest Income | $2,485,000 | $2,683,000 | $3,003,000 | $1,398,000 |
| Normalized Income | $-19,406,149 | $-46,173,170 | $-61,648,990 | $-87,466,910 |
| Net Income From Continuing And Discontinued Operation | $6,815,000 | $-45,997,000 | $-60,637,000 | $-86,575,000 |
| Total Operating Income As Reported | $-70,221,000 | $-110,379,000 | $-142,342,000 | $-203,564,000 |
| Net Income Common Stockholders | $-1,882,000 | $-55,890,000 | $-68,669,000 | $-94,607,000 |
| Net Income | $6,815,000 | $-45,997,000 | $-60,637,000 | $-86,575,000 |
| Net Income Including Noncontrolling Interests | $-32,915,000 | $-120,855,000 | $-154,154,000 | $-213,913,000 |
| Net Income Continuous Operations | $-32,915,000 | $-120,855,000 | $-154,154,000 | $-213,913,000 |
| Pretax Income | $-33,535,000 | $-120,543,000 | $-153,633,000 | $-213,464,000 |
| Special Income Charges | $27,127,000 | $861,000 | $-3,143,000 | $0 |
| Interest Income Non Operating | $2,485,000 | $2,683,000 | $3,003,000 | $1,398,000 |
| Operating Income | $-70,221,000 | $-111,240,000 | $-139,199,000 | $-203,564,000 |
| Depreciation Amortization Depletion Income Statement | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Depreciation And Amortization In Income Statement | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Amortization Of Intangibles Income Statement | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Gross Profit | $42,338,000 | $36,796,000 | $61,620,000 | $44,968,000 |
| Per Share | ||||
| Diluted EPS | $-0.07 | $-2.69 | $-8.47 | $-14.55 |
| Basic EPS | $-0.07 | $-2.69 | $-8.47 | $-14.55 |
| Other | ||||
| Tax Effect Of Unusual Items | $507,851 | $46,830 | $269,010 | $237,090 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,894,000 | $-104,714,000 | $-137,002,000 | $-194,823,000 |
| Total Unusual Items | $26,729,000 | $223,000 | $1,281,000 | $1,129,000 |
| Total Unusual Items Excluding Goodwill | $26,729,000 | $223,000 | $1,281,000 | $1,129,000 |
| Reconciled Depreciation | $4,661,000 | $4,464,000 | $5,997,000 | $9,353,000 |
| EBITDA (Bullshit earnings) | $-20,165,000 | $-104,491,000 | $-135,721,000 | $-193,694,000 |
| EBIT | $-24,826,000 | $-108,955,000 | $-141,718,000 | $-203,047,000 |
| Diluted Average Shares | $27,901,889 | $20,784,334 | $8,110,906 | $5,924,967 |
| Basic Average Shares | $27,901,889 | $20,784,334 | $8,110,906 | $5,924,967 |
| Diluted NI Availto Com Stockholders | $-1,882,000 | $-55,890,000 | $-68,669,000 | $-94,607,000 |
| Preferred Stock Dividends | $8,697,000 | $9,893,000 | $8,032,000 | $8,032,000 |
| Minority Interests | $39,730,000 | $74,858,000 | $93,517,000 | $127,338,000 |
| Tax Provision | $-620,000 | $312,000 | $521,000 | $449,000 |
| Gain On Sale Of Business | $27,127,000 | $0 | - | - |
| Impairment Of Capital Assets | $0 | $3,692,000 | $3,143,000 | - |
| Gain On Sale Of Security | $-398,000 | $-638,000 | $4,424,000 | $1,129,000 |
| Amortization | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Research And Development | $11,901,000 | $56,881,000 | $106,071,000 | $134,876,000 |
| Selling General And Administration | $96,400,000 | $87,731,000 | $90,981,000 | $113,656,000 |
| Other Special Charges | - | $-4,553,000 | - | - |
| Write Off | - | $3,692,000 | $3,143,000 | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $22,268,000 | $-9,126,000 | $2,257,000 | $14,524,000 |
| Total Assets | $185,548,000 | $144,223,000 | $167,526,000 | $294,301,000 |
| Total Non Current Assets | $61,707,000 | $53,852,000 | $50,504,000 | $63,869,000 |
| Other Non Current Assets | $1,621,000 | $2,283,000 | $6,722,000 | $3,661,000 |
| Investmentin Financial Assets | $17,660,000 | $2,585,000 | - | - |
| Goodwill And Other Intangible Assets | $27,605,000 | $31,863,000 | $20,287,000 | $27,197,000 |
| Other Intangible Assets | $27,605,000 | $31,863,000 | $20,287,000 | $27,197,000 |
| Current Assets | $123,841,000 | $90,371,000 | $117,022,000 | $230,432,000 |
| Other Current Assets | $4,895,000 | $7,110,000 | $10,500,000 | $9,661,000 |
| Assets Held For Sale Current | $0 | $1,165,000 | $0 | - |
| Inventory | $9,624,000 | $14,431,000 | $10,206,000 | $14,159,000 |
| Receivables | $29,941,000 | $10,402,000 | $15,389,000 | $28,346,000 |
| Accounts Receivable | $29,783,000 | $10,231,000 | $15,222,000 | $28,208,000 |
| Allowance For Doubtful Accounts Receivable | $-200,000 | $-600,000 | $-500,000 | $-400,000 |
| Gross Accounts Receivable | $29,983,000 | $10,831,000 | $15,722,000 | $28,608,000 |
| Cash Cash Equivalents And Short Term Investments | $79,381,000 | $57,263,000 | $80,927,000 | $178,266,000 |
| Cash And Cash Equivalents | $79,381,000 | $57,263,000 | $80,927,000 | $178,266,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $74,301,000 | $75,960,000 | $84,661,000 | $127,344,000 |
| Long Term Debt And Capital Lease Obligation | $72,174,000 | $72,712,000 | $79,138,000 | $114,714,000 |
| Long Term Debt | $59,502,000 | $57,962,000 | $60,856,000 | $93,142,000 |
| Current Debt And Capital Lease Obligation | $2,127,000 | $3,248,000 | $5,523,000 | $12,630,000 |
| Net Debt | - | $1,324,000 | - | - |
| Current Debt | - | $625,000 | $3,000,000 | $10,183,000 |
| Other Current Borrowings | - | $625,000 | $3,000,000 | $7,235,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $123,365,000 | $145,867,000 | $165,939,000 | $244,276,000 |
| Total Non Current Liabilities Net Minority Interest | $73,621,000 | $74,468,000 | $81,031,000 | $116,561,000 |
| Other Non Current Liabilities | $1,447,000 | $1,756,000 | $1,893,000 | $1,847,000 |
| Current Liabilities | $49,744,000 | $71,399,000 | $84,908,000 | $127,715,000 |
| Other Current Liabilities | $136,000 | $1,718,000 | $4,980,000 | $16,917,000 |
| Payables And Accrued Expenses | $45,304,000 | $63,309,000 | $70,328,000 | $94,479,000 |
| Payables | $16,399,000 | $33,942,000 | $37,668,000 | $60,593,000 |
| Other Payable | $1,805,000 | $1,374,000 | $2,015,000 | $2,627,000 |
| Total Tax Payable | $356,000 | $932,000 | $843,000 | $722,000 |
| Income Tax Payable | $356,000 | $932,000 | $843,000 | $722,000 |
| Accounts Payable | $14,238,000 | $31,636,000 | $34,810,000 | $57,244,000 |
| Interest Payable | - | - | $0 | $342,000 |
| Current Deferred Liabilities | - | - | - | $728,000 |
| Equity | ||||
| Common Stock Equity | $49,870,000 | $22,734,000 | $22,541,000 | $41,718,000 |
| Preferred Stock Equity | $3,000 | $3,000 | $3,000 | $3,000 |
| Total Equity Gross Minority Interest | $62,183,000 | $-1,644,000 | $1,587,000 | $50,025,000 |
| Stockholders Equity | $49,873,000 | $22,737,000 | $22,544,000 | $41,721,000 |
| Retained Earnings | $-734,052,000 | $-740,867,000 | $-694,870,000 | $-634,233,000 |
| Long Term Equity Investment | $17,660,000 | $2,585,000 | - | - |
| Other | ||||
| Preferred Shares Number | $3,427,138 | $3,427,138 | $3,427,138 | $3,427,138 |
| Ordinary Shares Number | $31,364,094 | $27,908,839 | $15,093,053 | $7,366,283 |
| Share Issued | $31,364,094 | $27,908,839 | $15,093,053 | $7,366,283 |
| Tangible Book Value | $22,265,000 | $-9,129,000 | $2,254,000 | $14,521,000 |
| Invested Capital | $109,372,000 | $81,321,000 | $86,397,000 | $145,043,000 |
| Working Capital | $74,097,000 | $18,972,000 | $32,114,000 | $102,717,000 |
| Capital Lease Obligations | $14,799,000 | $17,373,000 | $20,805,000 | $24,019,000 |
| Total Capitalization | $109,375,000 | $80,699,000 | $83,400,000 | $134,863,000 |
| Minority Interest | $12,310,000 | $-24,381,000 | $-20,957,000 | $8,304,000 |
| Additional Paid In Capital | $783,891,000 | $763,573,000 | $717,396,000 | $675,944,000 |
| Capital Stock | $34,000 | $31,000 | $18,000 | $10,000 |
| Common Stock | $31,000 | $28,000 | $15,000 | $7,000 |
| Preferred Stock | $3,000 | $3,000 | $3,000 | $3,000 |
| Long Term Capital Lease Obligation | $12,672,000 | $14,750,000 | $18,282,000 | $21,572,000 |
| Current Capital Lease Obligation | $2,127,000 | $2,623,000 | $2,523,000 | $2,447,000 |
| Current Provisions | $2,177,000 | $3,124,000 | $4,077,000 | $3,689,000 |
| Current Accrued Expenses | $28,905,000 | $29,367,000 | $32,660,000 | $33,886,000 |
| Investments And Advances | $17,660,000 | $2,585,000 | - | - |
| Available For Sale Securities | $17,660,000 | $2,585,000 | - | - |
| Net PPE | $14,821,000 | $17,121,000 | $23,495,000 | $33,011,000 |
| Accumulated Depreciation | $-5,144,000 | $-12,108,000 | $-8,892,000 | $-12,446,000 |
| Gross PPE | $19,965,000 | $29,229,000 | $32,387,000 | $45,457,000 |
| Leases | $5,470,000 | $13,175,000 | $13,175,000 | $13,175,000 |
| Other Properties | $12,302,000 | $13,861,000 | $16,990,000 | $19,991,000 |
| Machinery Furniture Equipment | $1,612,000 | $1,612,000 | $1,612,000 | $10,758,000 |
| Buildings And Improvements | $581,000 | $581,000 | $581,000 | $581,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-996,000 | $-513,000 | $-305,000 | $-429,000 |
| Finished Goods | $7,389,000 | $11,381,000 | $4,987,000 | $7,739,000 |
| Work In Process | $174,000 | $367,000 | $884,000 | $395,000 |
| Raw Materials | $3,057,000 | $3,196,000 | $4,640,000 | $6,454,000 |
| Duefrom Related Parties Current | $158,000 | $171,000 | $167,000 | $138,000 |
| Construction In Progress | - | $0 | $29,000 | $952,000 |
| Treasury Shares Number | - | - | $0 | - |
| Line Of Credit | - | - | $0 | $2,948,000 |
| Current Deferred Revenue | - | - | - | $728,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $9,772,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-65,777,000 | $-95,191,000 | $-136,323,000 | $-182,456,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-65,777,000 | $-80,191,000 | $-128,225,000 | $-179,401,000 |
| Cash Flow From Continuing Operating Activities | $-65,777,000 | $-80,191,000 | $-128,225,000 | $-179,401,000 |
| Operating Gains Losses | $-26,729,000 | $2,973,000 | $1,033,000 | $-874,000 |
| Investing Activities | ||||
| Investing Cash Flow | $10,121,000 | $-15,000,000 | $-2,103,000 | $-22,928,000 |
| Cash Flow From Continuing Investing Activities | $10,121,000 | $-15,000,000 | $-2,103,000 | $-22,928,000 |
| Capital Expenditure | - | $-15,000,000 | $-8,098,000 | $-3,055,000 |
| Net Other Investing Changes | - | - | $-5,000 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-265,000 | $0 | $-400,000 | $-1,196,000 |
| Issuance Of Capital Stock | $81,681,000 | $82,844,000 | $81,230,000 | $42,791,000 |
| Financing Cash Flow | $77,442,000 | $70,641,000 | $32,739,000 | $75,319,000 |
| Cash Flow From Continuing Financing Activities | $77,442,000 | $70,641,000 | $32,739,000 | $75,319,000 |
| Net Other Financing Charges | $-625,000 | $-1,250,000 | $-1,210,000 | $-7,124,000 |
| Cash Dividends Paid | $-664,000 | $-4,710,000 | $-8,768,000 | $-8,780,000 |
| Preferred Stock Dividend Paid | $0 | $-4,016,000 | $-8,032,000 | $-8,031,000 |
| Common Stock Dividend Paid | $-664,000 | $-694,000 | $-736,000 | $-749,000 |
| Net Preferred Stock Issuance | $-265,000 | $0 | $454,000 | $2,448,000 |
| Net Common Stock Issuance | $81,681,000 | $82,844,000 | $80,376,000 | $39,147,000 |
| Common Stock Issuance | $81,681,000 | $82,844,000 | $80,376,000 | $40,258,000 |
| Preferred Stock Issuance | - | $0 | $854,000 | $2,533,000 |
| Other | ||||
| Repayment Of Debt | $-5,636,000 | $-51,000,000 | $-81,323,000 | $-2,864,000 |
| Issuance Of Debt | $0 | $43,670,000 | $42,529,000 | $52,112,000 |
| Interest Paid Supplemental Data | $7,386,000 | $7,159,000 | $7,945,000 | $9,419,000 |
| Income Tax Paid Supplemental Data | $49,000 | $120,000 | - | $858,000 |
| End Cash Position | $80,601,000 | $58,815,000 | $83,365,000 | $180,954,000 |
| Beginning Cash Position | $58,815,000 | $83,365,000 | $180,954,000 | $307,964,000 |
| Changes In Cash | $21,786,000 | $-24,550,000 | $-97,589,000 | $-127,010,000 |
| Proceeds From Stock Option Exercised | $2,951,000 | $1,087,000 | $681,000 | $380,000 |
| Preferred Stock Payments | $-265,000 | $0 | $-400,000 | $-85,000 |
| Net Issuance Payments Of Debt | $-5,636,000 | $-7,330,000 | $-38,794,000 | $49,248,000 |
| Net Long Term Debt Issuance | $-5,636,000 | $-7,330,000 | $-35,846,000 | $47,112,000 |
| Long Term Debt Payments | $-5,636,000 | $-51,000,000 | $-50,375,000 | $0 |
| Long Term Debt Issuance | $0 | $43,670,000 | $14,529,000 | $47,112,000 |
| Net Business Purchase And Sale | $8,956,000 | $0 | $0 | $-20,000,000 |
| Sale Of Business | $8,956,000 | $0 | - | $0 |
| Net Intangibles Purchase And Sale | $0 | $-15,000,000 | $-8,035,000 | $-340,000 |
| Purchase Of Intangibles | $0 | $-15,000,000 | $-8,035,000 | $-340,000 |
| Net PPE Purchase And Sale | $1,165,000 | $0 | $5,937,000 | $-2,588,000 |
| Sale Of PPE | $1,165,000 | $0 | $6,000,000 | $127,000 |
| Change In Working Capital | $-25,096,000 | $-8,127,000 | $-12,519,000 | $-715,000 |
| Change In Other Current Liabilities | $-3,904,000 | $-2,416,000 | $-3,077,000 | $-2,211,000 |
| Change In Other Current Assets | $330,000 | $968,000 | $-808,000 | $344,000 |
| Change In Payables And Accrued Expense | $-8,547,000 | $-6,301,000 | $-24,261,000 | $8,726,000 |
| Change In Payable | $-8,547,000 | $-6,301,000 | $-24,261,000 | $8,726,000 |
| Change In Account Payable | $-7,971,000 | $-6,390,000 | $-24,382,000 | $8,349,000 |
| Change In Tax Payable | $-576,000 | $89,000 | $121,000 | $377,000 |
| Change In Income Tax Payable | $-576,000 | $89,000 | $121,000 | $377,000 |
| Change In Prepaid Assets | $1,546,000 | $-624,000 | $-848,000 | $-2,595,000 |
| Change In Inventory | $4,807,000 | $-4,225,000 | $3,953,000 | $1,744,000 |
| Change In Receivables | $-19,328,000 | $4,471,000 | $12,522,000 | $-4,840,000 |
| Changes In Account Receivables | $-19,341,000 | $4,475,000 | $12,551,000 | $-5,380,000 |
| Other Non Cash Items | $849,000 | $4,527,000 | $10,811,000 | $3,477,000 |
| Stock Based Compensation | $28,739,000 | $32,619,000 | $17,029,000 | $22,987,000 |
| Unrealized Gain Loss On Investment Securities | $-15,075,000 | $0 | - | $0 |
| Asset Impairment Charge | $-211,000 | $4,208,000 | $3,578,000 | $284,000 |
| Depreciation Amortization Depletion | $4,661,000 | $4,464,000 | $5,997,000 | $9,353,000 |
| Depreciation And Amortization | $4,661,000 | $4,464,000 | $5,997,000 | $9,353,000 |
| Amortization Cash Flow | $4,258,000 | $3,424,000 | $3,767,000 | $4,277,000 |
| Amortization Of Intangibles | $4,258,000 | $3,424,000 | $3,767,000 | $4,277,000 |
| Depreciation | $403,000 | $1,040,000 | $2,230,000 | $5,076,000 |
| Gain Loss On Investment Securities | $398,000 | $487,000 | $-4,424,000 | $-1,129,000 |
| Gain Loss On Sale Of PPE | $0 | $29,000 | $-1,466,000 | $255,000 |
| Gain Loss On Sale Of Business | $-27,127,000 | $0 | $4,127,000 | $0 |
| Net Income From Continuing Operations | $-32,915,000 | $-120,855,000 | $-154,154,000 | $-213,913,000 |
| Net Short Term Debt Issuance | - | $0 | $-2,948,000 | $2,136,000 |
| Short Term Debt Payments | - | $0 | $-30,948,000 | $-2,864,000 |
| Short Term Debt Issuance | - | $0 | $28,000,000 | $5,000,000 |
| Purchase Of PPE | - | $0 | $-63,000 | $-2,715,000 |
| Common Stock Payments | - | - | $0 | $-1,111,000 |
| Purchase Of Business | - | - | $0 | $-20,000,000 |
| Change In Other Working Capital | - | - | - | $-1,883,000 |
| Change In Accrued Expense | - | - | - | - |
| Change In Interest Payable | - | - | - | - |
Fetched: 2026-06-22